Jun 19th 2012 - Edison Investment Research today published a report on algeta entitled "ALSYMPCA Data Improves". In summary, the report says:
Updated data from the pivotal Phase III ALSYMPCA study of Alpharadin presented at ASCO confirm the 3.6 month increase in median survival and disclose a 5.5 month increase in time to first on-study skeletal-related event, both to a high statistical standard. Survival benefits were also confirmed in the pre-and post-docetaxel subgroups. Filing is now set for mid H2 and launch, pending approval, we assume in early 2013. We value Algeta at NOK11bn (US$1.9bn), equivalent to NOK258/share.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »